Avacta Group Plc (AIM: AVCT)
London
· Delayed Price · Currency is GBP · Price in GBX| Market Cap | 258.30M |
| Revenue (ttm) | 23.25M |
| Net Income (ttm) | -24.95M |
| Shares Out | 358.75M |
| EPS (ttm) | -0.09 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 578,722 |
| Open | 68.47 |
| Previous Close | 68.50 |
| Day's Range | 67.33 - 70.00 |
| 52-Week Range | 39.50 - 166.98 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 27, 2024 |
About Avacta Group
Avacta Group Plc develops cancer drugs and in vitro diagnostics in the United Kingdom, France, North America, South Korea, rest of Europe, and internationally. The company operates through Diagnostics and Therapeutics segments. It provides its proprietary Affimer and pre|CISION technology platforms, which is used to deliver a portfolio of differentiated th therapeutic and diagnostic products that addresses various markets. The company develops AVA6000, a peptide drug conjugate form of doxorubicin that is in Phase I clinical trial to treat local... [Read more]
Financial Performance
In 2023, Avacta Group's revenue was 23.25 million, an increase of 140.83% compared to the previous year's 9.65 million. Losses were -24.95 million, -31.90% less than in 2022.
Financial StatementsNews
Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors
Avacta Group plc Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors London, England; July 8, 2024; Avacta Group plc (AIM: AVCT), a life scien...